Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 5.3.1.9 - glucose-6-phosphate isomerase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
5'-nucleotidase deficiency
Enzymatic diagnosis in non-spherocytic hemolytic anemia.
[Hemolytic anemias caused by erythrocyte enzyme disorders]
Acquired Immunodeficiency Syndrome
Are syntax errors due to the amino acid sequence of neuroleukin involved in the pathogenesis of the acquired immunodeficiency syndrome (AIDS) and insulin dependent diabetes mellitus (IDDM)?
Enzyme abnormalities of patients with acquired immunodeficiency syndrome.
Immunohistochemistry of human immunodeficiency virus in the central nervous system and an hypothesis concerning the pathogenesis of AIDS meningoencephalomyelitis.
Laboratory aids to diagnosis--enzymes.
Molecular cloning and expression of neuroleukin, a neurotrophic factor for spinal and sensory neurons.
Adenocarcinoma
An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1.
Autocrine motility factor in pulmonary adenocarcinomas: results of an immunohistochemical study.
Autocrine motility factor receptor expression as a prognostic factor in pulmonary adenocarcinoma.
Autocrine motility factor receptor expression implies an unfavourable prognosis in resected stage I pulmonary adenocarcinomas.
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Adenocarcinoma of Lung
Nucleokinesis: distinct pattern of cell translocation in response to an autocrine motility factor-like substance or fibronectin.
adenylate kinase deficiency
Enzymatic diagnosis in non-spherocytic hemolytic anemia.
Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach.
Alzheimer Disease
Codon 129 polymorphism specific cerebrospinal fluid proteome pattern in sporadic creutzfeldt-jakob disease and the implication of glycolytic enzymes in prion-induced pathology.
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Impaired brain glucose metabolism in patients with Down syndrome.
Anemia
Inhibitory effect of mannose on erythrocyte defense against oxidants.
Isolation of novel animal cell lines defective in glycerolipid biosynthesis reveals mutations in glucose-6-phosphate isomerase.
On the serum activity of lactic acid dehydrogenase and phosphohexose isomerase in pernicious and hemolytic anemias.
Anemia, Diamond-Blackfan
Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach.
Anemia, Hemolytic
A Novel Mutation of Glucose Phosphate Isomerase (GPI) Causing Severe Neonatal Anemia Due to GPI Deficiency.
Amoxicillin-induced hemolytic anemia in a child with glucose 6-phosphate isomerase deficiency.
Congenital haemolytic anaemia resulting from glucose phosphate isomerase deficiency: genetics, clinical picture, and prenatal diagnosis.
Erythrocyte pyruvate kinase- and glucose phosphate isomerase deficiency: perturbation of glycolysis by structural defects and functional alterations of defective enzymes and its relation to the clinical severity of chronic hemolytic anemia.
First trimester monitoring of a pregnancy at risk for glucose phosphate isomerase deficiency.
Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia: a new variant (type Nordhorn). I. Clinical and genetic studies.
Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia: a new variant (type Nordhorn). II. Purification and biochemical properties of the defective enzyme.
Glucose phosphate isomerase deficiency with hereditary hemolytic anemia in a Spanish family: clinical and familial studies.
Glucose phosphate isomerase deficiency with hereditary nonspherocytic hemolytic anemia.
Glucose phosphate isomerase deficiency: biochemical and molecular genetic studies on the enzyme variants of two patients with severe haemolytic anaemia.
Glucose phosphate isomerase deficiency: enzymatic and familial characterization of Arg346His mutation.
Glucose Phosphate Isomerase Deficiency: High Prevalence of p.Arg347His Mutation in Indian Population Associated with Severe Hereditary Non-Spherocytic Hemolytic Anemia Coupled with Neurological Dysfunction.
Glucose-6-phosphate isomerase deficiency associated with nonspherocytic hemolytic anemia in the mouse: an animal model for the human disease.
Glucose-6-phosphate isomerase deficiency-Nahariya: extreme in vitro and in vivo lability of the mutant enzyme.
Glucose-6-phosphate isomerase deficiency.
Hereditary non-spherocytic hemolytic anemia and severe glucose phosphate isomerase deficiency in an Indian patient homozygous for the L487F mutation in the human GPI gene.
Hereditary nonspherocytic hemolytic anemia caused by red cell glucose-6-phosphate isomerase (GPI) deficiency in two Portuguese patients: Clinical features and molecular study.
Molecular analysis of glucose phosphate isomerase deficiency associated with hereditary hemolytic anemia.
Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency.
Molecular diagnosis of unexplained haemolytic anaemia using targeted next-generation sequencing panel revealed (p.Ala337Thr) novel mutation in GPI gene in two Indian patients.
Red cell glucose phosphate isomerase (GPI): a molecular study of three novel mutations associated with hereditary nonspherocytic hemolytic anemia.
Study of the molecular defects in glucose phosphate isomerase-deficient patients affected by chronic hemolytic anemia.
Successful long-term phenobarbital therapy of hyperbilirubinemia in congenital hemolytic anemia due to glucose phosphate isomerase deficiency.
The characterization of gene mutations for human glucose phosphate isomerase deficiency associated with chronic hemolytic anemia.
The crystal structure of human phosphoglucose isomerase at 1.6 A resolution: implications for catalytic mechanism, cytokine activity and haemolytic anaemia.
Two novel mutations (p.(Ser160Pro) and p.(Arg472Cys)) causing glucose-6-phosphate isomerase deficiency are associated with erythroid dysplasia and inappropriately suppressed hepcidin.
[A case of congenital nonspherocytic hemolytic anemia associated with defective glucose phosphate isomerase]
[Deficit of glucose phosphate isomerase in erythrocytes of a Polish girl with inherited hemolytic anemia]
[Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia]
[Glucose phosphate isomerase type Recklinghausen: a new enzyme variant with haemolytic anaemia (author's transl)]
Anemia, Hemolytic, Congenital
Congenital Hemolytic Anemia Because of Glucose Phosphate Isomerase Deficiency: Identification of 2 Novel Missense Mutations in the GPI Gene.
Glucose phosphate isomerase deficiency with hereditary hemolytic anemia in a Spanish family: clinical and familial studies.
Hemodialysis and kidney transplantation in a patient with glucose phosphate isomerase deficiency.
Inhibitory effect of mannose on erythrocyte defense against oxidants.
Molecular analysis of glucose phosphate isomerase deficiency associated with hereditary hemolytic anemia.
Successful long-term phenobarbital therapy of hyperbilirubinemia in congenital hemolytic anemia due to glucose phosphate isomerase deficiency.
Anemia, Hemolytic, Congenital Nonspherocytic
Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia: a new variant (type Nordhorn). I. Clinical and genetic studies.
Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia: a new variant (type Nordhorn). II. Purification and biochemical properties of the defective enzyme.
[A case of congenital nonspherocytic hemolytic anemia associated with defective glucose phosphate isomerase]
[Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia]
Anemia, Neonatal
A Novel Mutation of Glucose Phosphate Isomerase (GPI) Causing Severe Neonatal Anemia Due to GPI Deficiency.
Anemia, Refractory
Mechanisms of the acquired erythrocyte enzyme deficiencies in blood diseases.
Anemia, Sickle Cell
Red blood cell disorders in Rwandese neonates: screening for sickle cell disease and glucose-6-phosphate dehydrogenase deficiency.
Arthritis
18?F-Fluoride positron emission tomography/computed tomography for noninvasive in vivo quantification of pathophysiological bone metabolism in experimental murine arthritis.
A Glucose-6-Phosphate Isomerase Peptide Induces T and B Cell-Dependent Chronic Arthritis in C57BL/10 Mice: Arthritis without Reactive Oxygen Species and Complement.
A mouse herpesvirus induces relapse of experimental autoimmune arthritis by infection of the inflammatory target tissue.
A new model for rheumatoid arthritis?
A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models.
A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice.
Activation of Invariant NKT cells with glycolipid ligand ?-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis.
Adenosine 2a receptor signals block autoimmune arthritis by inhibiting pathogenic germinal center T follicular helper cells.
Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide.
Ameliorated course of glucose-6-phosphate isomerase (G6PI)-induced arthritis in IFN-? receptor knockout mice exposes an arthritis-promoting role of IFN-?.
Antigen-specific over-expression of human cartilage glycoprotein 39 on CD4+ CD25+ forkhead box protein 3+ regulatory T cells in the generation of glucose-6-phosphate isomerase-induced arthritis.
Arthritogenic monoclonal antibodies from K/BxN mice.
Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells.
Arthritogenic T cell epitope in glucose-6-phosphate isomerase-induced arthritis.
Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis.
Autoantibodies against glucose-6-phosphate isomerase are not a diagnostic marker for juvenile idiopathic arthritis.
Autoantibodies in juvenile idiopathic arthritis: glucose-6-phosphate isomerase is not a specific target.
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease.
CD4(+)CD25(+) Regulatory T Cells Selectively Diminish Systemic Autoreactivity in Arthritic K/BxN Mice.
Characterization of an Expanded IL-10-Producing-Suppressive T Cell Population Associated with Immune Tolerance.
Combination treatment with fingolimod and a pathogenic antigen prevents relapse of glucose-6-phosphate isomerase peptide-induced arthritis.
Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.
Crucial role of TNF?-induced adipose-related protein (TIARP) in the pathogenesis of autoimmune arthritis.
Diagnostic and prognostic values of anti glucose-6-phosphate isomerase antibodies in community-recruited patients with very early arthritis.
Efficacy of Combination Treatment with Fingolimod (FTY720) plus Pathogenic Autoantigen in a Glucose-6-phosphate Isomerase Peptide (GPI325-339)-induced Arthritis Mouse Model.
Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.
Functional Mechanism(s) of the Inhibition of Disease Progression by Combination Treatment with Fingolimod Plus Pathogenic Antigen in a Glucose-6-phosphate Isomerase Peptide-Induced Arthritis Mouse Model.
Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies: possible mechanism of autoantibody production.
Heterogeneous stock mice are susceptible to encephalomyelitis and antibody-initiated arthritis but not to collagen- and G6PI-induced arthritis.
How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease.
Hypoxia-induced upregulation of the glycolytic enzyme glucose-6-phosphate isomerase perpetuates rheumatoid arthritis.
Immunization with an immunodominant self-peptide derived from glucose-6-phosphate isomerase induces arthritis in DBA/1 mice.
Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice.
In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice.
In vivo molecular imaging of experimental joint inflammation by combined 18F-FDG positron emission tomography and computed tomography.
Incidence and severity of G6PI-induced arthritis are not increased in genetically distinct mouse strains upon aging.
Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis.
Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase.
Inhibition of Glycolysis Reduces Disease Severity in an Autoimmune Model of Rheumatoid Arthritis.
Interleukin-4 can be a key positive regulator of inflammatory arthritis.
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.
Lessons from animal models of arthritis.
Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders.
Mechanism of Immunoregulatory Properties of Vasoactive Intestinal Peptide in the K/BxN Mice Model of Autoimmune Arthritis.
Optimized protein kinase C? (PKC?) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.
Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model.
Quantification of arthritic bone degradation by analysis of 3D micro-computed tomography data.
Regulatory T cells control epitope spreading in autoimmune arthritis independent of cytotoxic T-lymphocyte antigen-4.
Regulatory T cells control the transition from acute into chronic inflammation in glucose-6-phosphate isomerase-induced arthritis.
Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes.
Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice.
The contribution of inflammation and bone destruction to pain in arthritis - a study in murine glucose-6-phosphate isomerase (G6PI)-induced arthritis.
The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation.
The K/BxN arthritis model.
The K/BxN mouse model of inflammatory arthritis: theory and practice.
The role and clinical implications of G6PI in experimental models of rheumatoid arthritis.
The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis.
The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis.
Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis.
Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis.
[Animal models for bone and joint disease. K/BxN mice - serum transferred arthritis -].
Arthritis, Experimental
Heterogeneous stock mice are susceptible to encephalomyelitis and antibody-initiated arthritis but not to collagen- and G6PI-induced arthritis.
Arthritis, Juvenile
Autoantibodies against glucose-6-phosphate isomerase are not a diagnostic marker for juvenile idiopathic arthritis.
Autoantibodies in juvenile idiopathic arthritis: glucose-6-phosphate isomerase is not a specific target.
Arthritis, Rheumatoid
Acid-induced conformational changes in phosphoglucose isomerase result in its increased cell surface association and deposition on fibronectin fibrils.
Activation of Invariant NKT cells with glycolipid ligand ?-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis.
Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity.
Anti-glucose-6-phosphate isomerase, anti-cyclic citrullinated peptide antibodies and HLA-DRB1 genotypes in Japanese patients with early rheumatoid arthritis.
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis.
Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis.
Autoantibodies to glucose-6-phosphate isomerase are elevated in the synovial fluid of rheumatoid arthritis patients.
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease.
Characterisation of Th1/Th2 type, glucose-6-phosphate isomerase reactive T cells in the generation of rheumatoid arthritis.
Detection of antibodies against glucose 6-phosphate isomerase in synovial fluid of rheumatoid arthritis using surface plasmon resonance (BIAcore).
Diagnostic value of glucose-6-phosphate isomerase in rheumatoid arthritis.
Differential MHC Class II Presentation of a Pathogenic Autoantigen during Health and Disease.
Dynamic visualization of a joint-specific autoimmune response through positron emission tomography.
Efficacy of Combination Treatment with Fingolimod (FTY720) plus Pathogenic Autoantigen in a Glucose-6-phosphate Isomerase Peptide (GPI325-339)-induced Arthritis Mouse Model.
Elevated Serum Glucose-6-Phosphate Isomerase Correlates with Histological Disease Activity and Clinical Improvement After Initiation of Therapy in Patients with Rheumatoid Arthritis.
Expression of autocrine motility-like factor in rheumatoid synovial fluid.
Glucose-6-Phosphate Isomerase (G6PI) Mediates Hypoxia-Induced Angiogenesis in Rheumatoid Arthritis.
Glucose-6-phosphate isomerase is associated with disease activity and declines in response to infliximab treatment in rheumatoid arthritis.
Glucose-6-phosphate isomerase is not a specific autoantigen in rheumatoid arthritis.
Glucose-6-phosphate isomerase promotes the proliferation and inhibits the apoptosis in fibroblast-like synoviocytes in rheumatoid arthritis.
High affinity glycosaminoglycan and autoantigen interaction explains joint specificity in a mouse model of rheumatoid arthritis.
Hypoxia-induced upregulation of the glycolytic enzyme glucose-6-phosphate isomerase perpetuates rheumatoid arthritis.
Insufficient autoantigen presentation and failure of tolerance in a mouse model of rheumatoid arthritis.
Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders.
Revisit of autoimmunity to glucose-6-phosphate isomerase in experimental and rheumatoid arthritis.
Value of serum glucose-6-phosphate isomerase in patients with rheumatoid arthritis and correlation with disease activity: A case-control study.
[Diagnostic value of glucose-6-phosphate isomerase in rheumatoid arthritis patients: systematic review]
[Significance of antibodies to the citrullinated glucose-6-phosphate isomerase peptides in rheumatoid arthritis].
[Significance of glucose-6-phosphate isomerase assay in early diagnosis of rheumatoid arthritis].
Asthenozoospermia
Proteomics analysis of asthenozoospermia and identification of glucose-6-phosphate isomerase as an important enzyme for sperm motility.
Astrocytoma
Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma.
Bone Resorption
Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Brain Injuries
Angiogenesis dysregulation in term asphyxiated newborns treated with hypothermia.
Breast Diseases
Clinical significance of serum spermine in breast cancer.
Breast Neoplasms
Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
Autocrine Motility Factor Modulates EGF-Mediated Invasion Signaling.
Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.
Biochemical studies in breast carcinoma. 1. Serum phosphohexose isomerase, lactate dehydrogenase and its isoenzyme changes.
Clinical significance of serum spermine in breast cancer.
Evaluation of phosphohexose isomerase as a metastasis marker in breast cancer patients.
Expression of Autocrine Motility Factor (AMF) and Its Receptor, AMFR, in Human Breast Cancer.
Insulin-like growth factor binding protein-3 interacts with autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and inhibits the AMF/PGI function.
Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells.
Metabolic changes in breast carcinoma. II. Phosphohexose isomerase and lactic dehydrogenase levels in serum.
Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer.
Phosphoglucose Isomerase/Autocrine Motility Factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.
Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells.
Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.
Serum tumor markers in metastatic breast cancer and course of disease.
Silencing of Autocrine Motility Factor Induces Mesenchymal-to-Epithelial Transition and Suppression of Osteosarcoma Pulmonary Metastasis.
Simultaneous microscopic and biochemical findings in breast carcinoma. Preliminary results.
Synergistic effects of autocrine motility factor and methyl jasmonate on human breast cancer cells.
The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease.
The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer.
THE VALUE OF SERUM PHOSPHOHEXOSE ISOMERASE AS AN INDEX OF METASTATIC BREAST CARCINOMA ACTIVITY.
[Prognostic significance of serum phosphohexose isomerase in metastatic breast cancer]
[The determination of phosphohexose isomerase in patients with cancer of breast and uterus. A comparison with other tests (author's transl)]
Carcinogenesis
Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3.
Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
Carcinoma
A trial of phosphohexose isomerase as a means of detecting cervical carcinoma.
Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma.
Activities of phosphohexose isomerase and other glycolytic enzymes in normal and tumor tissue of patients with neoplastic diseases: comparison with serum activities and correlation to tumor staging and grading.
Autocrine motility factor and its receptor expressions in human oral squamous cell carcinoma (SCC) cells.
Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Autocrine motility factor-receptor in human bladder-carcinoma - gene-expression, loss of cell-contact regulation and chromosomal mapping.
Clinical significance of serum lactate dehydrogenase, phosphohexose isomerase, aldolase and hexokinase in prostatic carcinoma.
Combined use of serum enzyme levels as tumor markers in cervical carcinoma patients.
Comparison of serum phosphohexose isomerase activity and urinary calcium excretion in a patient with metastatic mammary carcinoma.
Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Diagnostic and prognostic significance of serum phosphohexose isomerase, aldolase and hexokinase in carcinoma cervix.
Differential expression and pathological significance of autocrine motility factor/glucose-6-phosphate isomerase expression in human lung carcinomas.
ENZYME STUDIES IN CEREBRAL TUMOURS. LACTATE DEHYDROGENASE, GLUCOSE PHOSPHATE ISOMERASE, ACID AND ALKALINE PHOSPHATASE IN PLASMA, VENTRICULAR CEREBROSPINAL FLUID AND TUMOUR CYST FLUID FROM CASES OF GLIOMA AND CEREBRAL SECONDARY CARCINOMA.
Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma.
Improved prognosis assessment for patients with bladder carcinoma.
Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.
Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
Molecular association of glucose-6-phosphate isomerase and pyruvate kinase M2 with glyceraldehyde-3-phosphate dehydrogenase in cancer cells.
Possible use of phosphohexose isomerase as a preliminary to exfoliative cytology in screening for cervical carcinoma.
Purification and characterization of phosphohexose isomerase from human gastrointestinal carcinoma and its potential relationship to neuroleukin.
Serum enzymes in patients with carcinoma of lung: lactic-acid dehydrogenase, phosphohexose isomerase, alkaline phosphatase and glutamic oxaloacetic transaminase.
Serum phosphohexose isomerase in cancer. III. As an index of tumor growth in metastatic carcinoma of the prostate.
Serum phosphohexose isomerase in cancer. II. As an index of tumor growth in metastatic carcinoma of the breast.
Significance of serum phosphohexose isomerase, hexokinase and aldolase in carcinoma ovary.
The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease.
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
Variants of phosphohexose isomerase in gastrointestinal and mammary carcinoma: isoelectric focusing patterns of normal and tumor tissues derived from surgical specimens of the same patient.
[Detection of early tumor reactions in irradiation of tumors of the gastrointestinal tract by measuring the onco-radiogenic enzyme peak of glucosephosphate isomerase]
[Possibilities for optimization of radiotherapy of esophageal carcinoma through measurement of the oncoradiogenic enzyme peak of glucosephosphate isomerase]
[Possibilities for optimizing radiotherapy of cancers of the ENT area by measuring oncoradiogenic enzyme peaks of glucose-6-phosphate isomerase]
[Quantitative studies of lysozyme and phosphohexose isomerase enzymes in mixed saliva in oral squamous epithelial carcinoma]
Carcinoma, Ehrlich Tumor
Glucose-6-phosphate isomerase from Ehrlich ascites tumor cells: purification and some properties.
Carcinoma, Hepatocellular
AMF/PGI transactivates the MMP-3 gene through the activation of Src-RhoA-phosphatidylinositol 3-kinase signaling to induce hepatoma cell migration.
Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins.
Effect of Plumbagin on some glucose metabolising enzymes studied in rats in experimental hepatoma.
Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma.
Genetic variants in glucose-6-phosphate isomerase gene as prognosis predictors in hepatocellular carcinoma.
Human umbilical cord perivascular cells exhibited enhanced migration capacity towards hepatocellular carcinoma in comparison with bone marrow mesenchymal stromal cells: a role for autocrine motility factor receptor.
Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma.
Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3.
Modulating effect of Semecarpus anacardium Linn. nut extract on glucose metabolizing enzymes in aflatoxin B1-induced experimental hepatocellular carcinoma.
Modulatory Role of Shorea robusta Bark on Glucose-metabolizing Enzymes in Diethylnitrosamine Induced Hepatocellular Carcinoma in Rats.
Phosphohexose isomerase activity as a tumor marker in hepatoma bearing rats (Yoshida A.H. 130).
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Carcinoma, Non-Small-Cell Lung
Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer.
Carcinoma, Renal Cell
Insulin-induced gene 1 (INSIG1) inhibits HIV-1 production by degrading Gag via activity of the ubiquitin ligase TRC8.
Phosphohexose isomerase in hypernephroma. Significance as serum tumor marker, comparison to other glycolytic enzymes and isozyme patterns in normal and tumor tissue.
Carcinoma, Squamous Cell
Regulation of cell motility via high and low affinity autocrine motility factor (AMF) receptor in human oral squamous carcinoma cells.
Carcinoma, Transitional Cell
Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Cataract
[Variation of some enzymatic activities of the rat crystalline lens in experimental galactose cataract (lactate dehydrogenase, leucine aminopeptidase, phosphoglucose isomerase]
Cerebrovascular Disorders
[Effect of intravenous glucose load on blood glucose and fructose level and glucose-6-phosphate isomerase activity in serum of patients with acute cerebrovascular disease in its earliest phase]
Cholecystitis
[Blood serum phosphohexose isomerase in cholecystitis]
Cholestasis, Extrahepatic
Glucose phosphate isomerase and glutathione reductase in benign and malignant extrahepatic cholestasis.
Chordoma
The nature of cytoplasmic vacuoles in chordoma cells. A correlative enzyme and electron microscopic histochemical study.
Choriocarcinoma
Enzymes of normal and malignant trophoblast: phosphoglucose isomerase, phosphoglucomutase, hexokinase, lactate dehydrogenase, and alkaline phosphatase.
Expression and function of autocrine motility factor receptor in human choriocarcinoma.
Colitis, Ulcerative
Emerging views of mitophagy in immunity and autoimmune diseases.
Colonic Diseases
Quantitation and immunochemical characterization of carcinoembryonic antigen and glucose phosphate isomerase in blood and washings of patients with gastric and colonic diseases.
Colonic Neoplasms
Carcinoembryonic antigen and glucose phosphate isomerase in a human colonic cancer model (GW-39).
The crystal structure of a multifunctional protein: phosphoglucose isomerase/autocrine motility factor/neuroleukin.
Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase.
Colorectal Neoplasms
Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases.
Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence.
Phosphoglucose isomerase enhances colorectal cancer metastasis.
Prognostic significance of autocrine motility factor receptor expression by colorectal cancer and lymph node metastases.
Serum phosphohexose isomerase activities in patients with colorectal cancer.
Congenital Abnormalities
Genetic and molecular mechanisms of the congenital defects in glucose phosphate isomerase activity: studies of four families.
Conjunctivitis
Genes for serum amyloid A proteins map to Chromosome 7 in the mouse.
Crohn Disease
Emerging views of mitophagy in immunity and autoimmune diseases.
Cysts
Cloning of two putative Giardia lamblia glucosamine 6-phosphate isomerase genes only one of which is transcriptionally activated during encystment.
Cystic intracranial tumours. Cyst fluid, biochemical changes and computerised tomographic findings.
ENZYME STUDIES IN CEREBRAL TUMOURS. LACTATE DEHYDROGENASE, GLUCOSE PHOSPHATE ISOMERASE, ACID AND ALKALINE PHOSPHATASE IN PLASMA, VENTRICULAR CEREBROSPINAL FLUID AND TUMOUR CYST FLUID FROM CASES OF GLIOMA AND CEREBRAL SECONDARY CARCINOMA.
Variations in Echinococcus granulosus of bovine origin identified by enzyme electrophoresis.
[Phosphohexose isomerase in cyst fluids and effusions as a complement to cytological diagnosis]
Dementia
Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases.
Dementia, Vascular
Codon 129 polymorphism specific cerebrospinal fluid proteome pattern in sporadic creutzfeldt-jakob disease and the implication of glycolytic enzymes in prion-induced pathology.
Diabetes Mellitus
Activation of hexokinase by mild insulin dependent diabetes mellitus in rat erythrocytes.
Are syntax errors due to the amino acid sequence of neuroleukin involved in the pathogenesis of the acquired immunodeficiency syndrome (AIDS) and insulin dependent diabetes mellitus (IDDM)?
Diphtheria
Regulatory T cells control epitope spreading in autoimmune arthritis independent of cytotoxic T-lymphocyte antigen-4.
Dysentery
The zymodemes of Entamoeba histolytica in New Delhi, India.
Echinococcosis
Partial purification and properties of ovine liver Echinococcus granulosus protoscolices phospholgucose isomerase.
Endometrial Neoplasms
AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma.
Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1.
Autocrine motility factor promotes epithelial-mesenchymal transition in endometrial cancer via MAPK signaling pathway.
Enzymes of glucose metabolism in carcinoma of the cervix and endometrium of the human uterus.
POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
Therapeutic potential of riboflavin, niacin and ascorbic Acid on carbohydrate metabolizing enzymes in secondary endometrial carcinoma bearing rats.
Esophageal Squamous Cell Carcinoma
Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma.
Fatty Liver
Secreted phosphoglucose isomerase is a novel biomarker of nonalcoholic fatty liver in mice and humans.
Fibrosarcoma
Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma.
Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence.
Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
Expression of autocrine motility factor receptor in serum- and protein-independent fibrosarcoma cells: implications for autonomy in tumor-cell motility and metastasis.
Production of a motility factor by a newly established lung adenocarcinoma cell line.
Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor.
Silencing of Autocrine Motility Factor Induces Mesenchymal-to-Epithelial Transition and Suppression of Osteosarcoma Pulmonary Metastasis.
Fructose Intolerance
Inhibition of glucose phosphate isomerase by metabolic intermediates of fructose.
[Influence of ACTH on some aspects of hydrocarbonate metabolism. II. Development of glycemia, fructosemia and phosphohexose isomerase (IFH) in adrenalectomized and normal rats]
Gastrointestinal Neoplasms
Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer.
Significance of serum phosphohexose isomerase in gastrointestinal cancer at different stages.
[Combination of cancer markers in the detection and prognosis of digestive system tumors]
Genetic Diseases, Inborn
Glucose phosphate isomerase deficiency: enzymatic and familial characterization of Arg346His mutation.
Glucose Phosphate Isomerase Deficiency: High Prevalence of p.Arg347His Mutation in Indian Population Associated with Severe Hereditary Non-Spherocytic Hemolytic Anemia Coupled with Neurological Dysfunction.
Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency.
Molecular diagnosis of unexplained haemolytic anaemia using targeted next-generation sequencing panel revealed (p.Ala337Thr) novel mutation in GPI gene in two Indian patients.
Two novel mutations (p.(Ser160Pro) and p.(Arg472Cys)) causing glucose-6-phosphate isomerase deficiency are associated with erythroid dysplasia and inappropriately suppressed hepcidin.
Glioblastoma
Association between autocrine motility factor receptor gene polymorphism (rs2440472, rs373191257) and glioblastoma multiform in a representative Iranian population.
Silencing of phosphoglucose isomerase/autocrine motility factor decreases U87 human glioblastoma cell migration.
The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects.
Glioma
ENZYME STUDIES IN CEREBRAL TUMOURS. LACTATE DEHYDROGENASE, GLUCOSE PHOSPHATE ISOMERASE, ACID AND ALKALINE PHOSPHATASE IN PLASMA, VENTRICULAR CEREBROSPINAL FLUID AND TUMOUR CYST FLUID FROM CASES OF GLIOMA AND CEREBRAL SECONDARY CARCINOMA.
Inhibition of IRE1 modifies hypoxic regulation of G6PD, GPI, TKT, TALDO1, PGLS and RPIA genes expression in U87 glioma cells.
Neuroleukin secretion is highly regulated in T cells but constitutive in C6 glioma cells.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
A combined system for the study of glutathione metabolism in erythrocytes.
Combined erythrocyte phosphohexose isomerase and glucose-6-phosphate dehydrogenase deficiency.
Combined glucose phosphate isomerase and glucose-6-phosphate dehydrogenase deficiency of erythrocytes.
glucose-6-phosphate isomerase deficiency
A combined system for the study of glutathione metabolism in erythrocytes.
A new variant of glucosephosphate isomerase deficiency.
Amoxicillin-induced hemolytic anemia in a child with glucose 6-phosphate isomerase deficiency.
Attenuation of Hemolysis Due to Glucose-6-Phosphate Isomerase Deficiency With Ketogenic Diet - A Case Report.
Clinical and Molecular Spectrum of Glucose-6-Phosphate Isomerase Deficiency. Report of 12 New Cases.
Congenital haemolytic anaemia resulting from glucose phosphate isomerase deficiency: genetics, clinical picture, and prenatal diagnosis.
Congenital Hemolytic Anemia Because of Glucose Phosphate Isomerase Deficiency: Identification of 2 Novel Missense Mutations in the GPI Gene.
Detection of phosphohexose isomerase deficiency in human fibroblast cultures.
DNA sequence abnormalities in human glucose 6-phosphate isomerase deficiency.
Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
Enzymatic diagnosis in non-spherocytic hemolytic anemia.
Erythrocyte pyruvate kinase- and glucose phosphate isomerase deficiency: perturbation of glycolysis by structural defects and functional alterations of defective enzymes and its relation to the clinical severity of chronic hemolytic anemia.
First trimester monitoring of a pregnancy at risk for glucose phosphate isomerase deficiency.
Glucose phosphate isomerase (GPI) Tadikonda: Characterization of a novel Pro340Ser mutation.
Glucose phosphate isomerase deficiency as a cause of hydrops fetalis.
Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia: a new variant (type Nordhorn). I. Clinical and genetic studies.
Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia: a new variant (type Nordhorn). II. Purification and biochemical properties of the defective enzyme.
Glucose phosphate isomerase deficiency with hereditary hemolytic anemia in a Spanish family: clinical and familial studies.
Glucose phosphate isomerase deficiency with hereditary nonspherocytic hemolytic anemia.
Glucose phosphate isomerase deficiency. Unusual acute hemolytic crisis in a middle-aged woman.
Glucose phosphate isomerase deficiency: biochemical and molecular genetic studies on the enzyme variants of two patients with severe haemolytic anaemia.
Glucose phosphate isomerase deficiency: enzymatic and familial characterization of Arg346His mutation.
Glucose Phosphate Isomerase Deficiency: High Prevalence of p.Arg347His Mutation in Indian Population Associated with Severe Hereditary Non-Spherocytic Hemolytic Anemia Coupled with Neurological Dysfunction.
Glucose-6-phosphate isomerase deficiency associated with nonspherocytic hemolytic anemia in the mouse: an animal model for the human disease.
Glucose-6-phosphate isomerase deficiency results in mTOR activation, failed translocation of lipin 1? to the nucleus and hypersensitivity to glucose: Implications for the inherited glycolytic disease.
Glucose-6-phosphate isomerase deficiency-Nahariya: extreme in vitro and in vivo lability of the mutant enzyme.
Glucose-6-phosphate isomerase deficiency.
Haematological studies in a new variant of glucosephosphate isomerase deficiency (GPI Utrecht).
Hematologically important mutations: molecular abnormalities of glucose phosphate isomerase deficiency.
Hemodialysis and kidney transplantation in a patient with glucose phosphate isomerase deficiency.
Hereditary non-spherocytic hemolytic anemia and severe glucose phosphate isomerase deficiency in an Indian patient homozygous for the L487F mutation in the human GPI gene.
Mechanisms of the acquired erythrocyte enzyme deficiencies in blood diseases.
Molecular analysis of glucose phosphate isomerase deficiency associated with hereditary hemolytic anemia.
Molecular characterization of glucose-6-phosphate isomerase deficiency in a mammalian cell mutant.
Priapism caused by glucose phosphate isomerase deficiency.
Red blood cell disorders in Rwandese neonates: screening for sickle cell disease and glucose-6-phosphate dehydrogenase deficiency.
Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach.
Successful long-term phenobarbital therapy of hyperbilirubinemia in congenital hemolytic anemia due to glucose phosphate isomerase deficiency.
Successful treatment of fetal hemolytic disease due to glucose phosphate isomerase deficiency (GPI) using repeated intrauterine transfusions: a case report.
The characterization of gene mutations for human glucose phosphate isomerase deficiency associated with chronic hemolytic anemia.
Two novel mutations (p.(Ser160Pro) and p.(Arg472Cys)) causing glucose-6-phosphate isomerase deficiency are associated with erythroid dysplasia and inappropriately suppressed hepcidin.
[Glucose phosphate isomerase deficiency with congenital nonspherocytic hemolytic anemia]
[Two cases in a family with new variants of glucose phosphate isomerase deficiency (author's transl)]
Glucosephosphate Dehydrogenase Deficiency
Combined erythrocyte phosphohexose isomerase and glucose-6-phosphate dehydrogenase deficiency.
Combined glucose phosphate isomerase and glucose-6-phosphate dehydrogenase deficiency of erythrocytes.
glutathione synthase deficiency
Enzymatic diagnosis in non-spherocytic hemolytic anemia.
glyceraldehyde-3-phosphate dehydrogenase (nad(p)+) (phosphorylating) deficiency
A simple screening procedure for glucose phosphate isomerase, phosphofructokinase, aldolase and glyceraldehyde-3-phosphate dehydrogenase deficiencies.
Graft vs Host Disease
Antibody-facilitated chimeras. Stem cell allotransplantation using antihost major histocompatibility complex monoclonal antibodies instead of lethal irradiation for host conditioning.
Head and Neck Neoplasms
Serum phosphohexose isomerase levels in patients with head and neck cancer.
Hematologic Diseases
[Behavior of phosphohexose isomerase activity (PHI) in the serum, pleural effusions, and ascitic fluids of subjects with malignant hematologic diseases and tumors]
Hepatitis
[Changes in the serum phosphohexose isomerase and leucine aminopeptidase levels during lysozyme treatment of viral hepatitis in childhood]
[Serum phosphohexose isomerase in healthy children and those with viral hepatitis]
Hydrops Fetalis
Congenital haemolytic anaemia resulting from glucose phosphate isomerase deficiency: genetics, clinical picture, and prenatal diagnosis.
Glucose phosphate isomerase (GPI) Tadikonda: Characterization of a novel Pro340Ser mutation.
Glucose phosphate isomerase deficiency as a cause of hydrops fetalis.
Hypersensitivity
Glucose-6-phosphate isomerase deficiency results in mTOR activation, failed translocation of lipin 1? to the nucleus and hypersensitivity to glucose: Implications for the inherited glycolytic disease.
Hyperthyroidism
Adaptation of red cell enzymes and intermediates in metabolic disorders.
Hypoglycemia
Adaptation of red cell enzymes and intermediates in metabolic disorders.
Modeling cancer glycolysis under hypoglycemia, and the role played by the differential expression of glycolytic isoforms.
Hypoxia, Brain
[Effect of hypoxia on carbohydrate metabolism in scorpion tissues]
Infections
Autoantigens and immune pathways in rheumatoid arthritis.
Differential expression of growth factors at the cellular level in virus-infected brain.
Electrophoretic variants of enzymes in isolates of Plasmodium falciparum, P. malariae and P. vivax from Thailand.
The effects of Minchinia nelsoni infection on enzyme levels in Crassostrea virginica. II. Serum phosphohexose isomerase.
Trypanosoma brucei infection induces apoptosis and up-regulates neuroleukin expression in the cerebellum.
Inflammatory Bowel Diseases
Emerging views of mitophagy in immunity and autoimmune diseases.
Intestinal Diseases
Serum phosphohexose isomerase activities in patients with colorectal cancer.
Kidney Neoplasms
Serum protein profiles in carcinoma of the kidney.
Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer--an update.
Leukemia
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells.
Down-regulation of Phosphoglucose Isomerase/Autocrine Motility Factor Enhances Gensenoside Rh2 Pharmacological Action on Leukemia KG1? Cells.
Neuroleukin mediated differentiation induction of myelogenous leukemia cells.
Plasma and intracellular levels of lactate dehydrogenase, phosphohexose isomerase and lysozyme activity in acute leukemia.
Plasma lactic dehydrogenase and phosphohexose isomerase in leukemia.
Studies on glycolytic enzymes in relation to cancer. I. Serum phosphohexose isomerase and aldolase in leukemia.
[ACTIVITY OF SERUM PHOSPHOHEXOSE ISOMERASE IN LEUKEMIA.]
Leukemia, Lymphocytic, Chronic, B-Cell
The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia.
Leukemia, Monocytic, Acute
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Plasma and intracellular levels of lactate dehydrogenase, phosphohexose isomerase and lysozyme activity in acute leukemia.
Puncta intended: connecting the dots between autophagy and cell stress networks.
Leukemia, Myeloid
A novel binding of GTP stabilizes the structure and modulates the activities of human phosphoglucose isomerase/autocrine motility factor.
Neuroleukin mediated differentiation induction of myelogenous leukemia cells.
The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase.
Leukemia, Myeloid, Acute
Human leukocyte glucose-phosphate-isomerase purification by affinity elution and immunological study.
Mechanisms of the acquired erythrocyte enzyme deficiencies in blood diseases.
Plasma and intracellular levels of lactate dehydrogenase, phosphohexose isomerase and lysozyme activity in acute leukemia.
Liver Cirrhosis, Biliary
Emerging views of mitophagy in immunity and autoimmune diseases.
Liver Diseases
Diagnostic value of activity of malic dehydrogenase and phosphohexose isomerase; preliminary report of findings in patients with myocardial infarction and liver disease.
Liver Neoplasms
The effect of autocrine motility factor alone and in combination with methyl jasmonate on liver cancer cell growth.
Lung Neoplasms
Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer.
Autocrine motility factor receptor gene expression and cell motility in lung cancer cell lines.
Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer.
Effect of capsaicin on glucose metabolism studied in experimental lung carcinogenesis.
Phosphohexose isomerase and carcinoembryonic antigen in the sera of patients with primary lung cancer.
Phosphohexose isomerase in lung cancer.
Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer.
The value of tumour markers in lung cancer.
[Value of serum phosphohexose isomerase in the diagnosis and prognosis of lung cancer]
Lupus Erythematosus, Systemic
Emerging views of mitophagy in immunity and autoimmune diseases.
Lymphatic Metastasis
Prognostic significance of autocrine motility factor receptor expression by colorectal cancer and lymph node metastases.
Lymphoma
Intracellular lactic dehydrogenase and phosphohexose isomerase activity in leukaemia and malignant lymphoma.
Quantitative immunoassay of recombinant murine neuroleukin.
Lymphoma, Non-Hodgkin
Intracellular lactic dehydrogenase and phosphohexose isomerase activity in leukaemia and malignant lymphoma.
Lymphopenia
Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells.
Machado-Joseph Disease
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Malaria
Studies on enzyme variation in the murine malaria parasites Plasmodium berghei, P. yoelii, P. vinckei and P. chabaudi by starch gel electrophoresis.
Malnutrition
The metabolic flow rate through the phosphopyruvate hydratase and glucose phosphate isomerase steps of glycolysis in normal rat liver, in cirrhosis, and in quantitative undernutrition.
Melanoma
Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization.
Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants.
Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion.
Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells.
Autotaxin is an exoenzyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities.
Autotaxin is an N-linked glycoprotein but the sugar moieties are not needed for its stimulation of cellular motility.
Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Emerging views of mitophagy in immunity and autoimmune diseases.
Expression of autocrine motility factor receptor in cutaneous malignant melanoma.
Heterogeneity of the motility responses in malignant tumor cells: a biological basis for the diversity and homing of metastatic cells.
Identification and characterization of autocrine-motility-factor-like activity in oral squamous-cell-carcinoma cells.
Osteopontin.
Pertussis toxin inhibits stimulated motility independently of the adenylate cyclase pathway in human melanoma cells.
Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8.
Production of a motility factor by a newly established lung adenocarcinoma cell line.
Purification of B16-F1 melanoma autocrine motility factor and its receptor.
Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Serum Autotaxin is not a Useful Biomarker for Ovarian Cancer.
Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
[Significance of serum autotaxin activity in gastrointestinal disease]
Meningitis
Clinical significance and source of raised catalytic activities of phosphohexose isomerase in the CSF in meningitis.
Phosphohexose isomerase activity of cerebrospinal fluid. Activity in bacterial meningitis and other neurological diseases.
Phosphohexose isomerase in cerebrospinal fluid in meningitis.
[Significance of lactate level, lysozyme concentration and phosphohexose isomerase activity in the cerebrospinal fluid in the differential diagnosis of meningitis]
Meningitis, Bacterial
Clinical significance and source of raised catalytic activities of phosphohexose isomerase in the CSF in meningitis.
Phosphohexose isomerase activity of cerebrospinal fluid. Activity in bacterial meningitis and other neurological diseases.
Meningitis, Viral
Clinical significance and source of raised catalytic activities of phosphohexose isomerase in the CSF in meningitis.
Phosphohexose isomerase in cerebrospinal fluid in meningitis.
Multiple Myeloma
Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors.
Myocardial Infarction
Diagnostic value of activity of malic dehydrogenase and phosphohexose isomerase; preliminary report of findings in patients with myocardial infarction and liver disease.
[Serum phosphohexose isomerase in the diagnosis of myocardial infarct]
[Value of phosphohexose isomerase (PHI) determination in myocardial infarct]
Myoclonic Epilepsies, Progressive
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Neoplasm Metastasis
Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma.
Activation of small GTPase Rho is required for autocrine motility factor signaling.
Association between autocrine motility factor receptor gene polymorphism (rs2440472, rs373191257) and glioblastoma multiform in a representative Iranian population.
Autocrine motility factor and its receptor: role in cell locomotion and metastasis.
Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization.
Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells.
Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells.
Autocrine motility factor signaling enhances pancreatic cancer metastasis.
Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression.
Calibration of the dianionic phosphate group: Validation on the recognition site of the homodimeric enzyme phosphoglucose isomerase.
Carbohydrate-based electrochemical biosensor for detection of a cancer biomarker in human plasma.
Carcinoembryonic antigen and phosphohexose isomerase, gammaglutamyl transpeptidase and lactate dehydorgenase levels in patients with and without liver metastases.
Cell motility, a principal requirement for metastasis.
Crystal structures of mouse autocrine motility factor in complex with carbohydrate phosphate inhibitors provide insight into structure-activity relationship of the inhibitors.
Crystallization and preliminary X-ray crystallographic studies of mouse autocrine motility factor.
Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation.
Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence.
Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma.
Evaluation of phosphohexose isomerase as a metastasis marker in breast cancer patients.
Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells.
Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer.
Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence.
Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma.
Expression of autocrine motility factor receptor in serum- and protein-independent fibrosarcoma cells: implications for autonomy in tumor-cell motility and metastasis.
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
Hyperthermia reduces migration of osteosarcoma by suppression of autocrine motility factor.
Identification of metastasis-associated genes by transcriptional profiling of a pair of metastatic versus non-metastatic human mammary carcinoma cell lines.
Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3.
Inhibition mechanism of cytokine activity of human autocrine motility factor examined by crystal structure analyses and site-directed mutagenesis studies.
Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway.
Novel N-substituted 5-phosphate-d-arabinonamide derivatives as strong inhibitors of phosphoglucose isomerases: Synthesis, structure-activity relationship and crystallographic studies.
Overexpression of autocrine motility factor receptor (AMFR) in NIH3T3 fibroblasts induces cell transformation.
Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts.
Phosphoglucose isomerase enhances colorectal cancer metastasis.
Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer.
Phosphoglucose Isomerase/Autocrine Motility Factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.
Prognostic significance of autocrine motility factor receptor expression by colorectal cancer and lymph node metastases.
Pulmonary metastatic lesion of endolymphatic stromal myosis expresses metastasis-related genes but not invasion-related matrix type metalloproteinase.
Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis.
Regulation of cell motility via high and low affinity autocrine motility factor (AMF) receptor in human oral squamous carcinoma cells.
Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling.
Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE.
Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14.
Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.
Research models and mesenchymal/epithelial plasticity of osteosarcoma.
Serum protein profiles in carcinoma of the kidney.
Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer.
Silencing of Autocrine Motility Factor Induces Mesenchymal-to-Epithelial Transition and Suppression of Osteosarcoma Pulmonary Metastasis.
Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
Suppression of melanoma cell motility factor receptor expression by retinoic acid.
Synergistic effects of autocrine motility factor and methyl jasmonate on human breast cancer cells.
The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein.
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
The role of autocrine motility factor in tumor and tumor microenvironment.
The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum.
Tumor autocrine motility factor is an angiogenic factor hat stimulates endothelial cell motility.
Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility.
Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide.
Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.
[Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm]
[Principles of tumor invasion and metastasis]
[Significance of serum autotaxin activity in gastrointestinal disease]
[The role of autocrine motility factor receptor in metastasis]
Neoplasms
6-phosphogluconate dehydrogenase, glucose-6-phosphate dehydrogenase, glucose-6-phosphate isomerase, and hexokinase activity ratios in some human tumor cytosols.
A comparison of three blood tests for cancer.
A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells.
A new method for evaluation of urinary autocrine motility factor and tumor cell collagenase stimulating factor as markers for urinary tract cancers.
Activation of small GTPase Rho is required for autocrine motility factor signaling.
Activities of phosphohexose isomerase and other glycolytic enzymes in normal and tumor tissue of patients with neoplastic diseases: comparison with serum activities and correlation to tumor staging and grading.
AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma.
Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors.
An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1.
Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia.
Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
Autocrine motility factor (neuroleukin, phosphohexose isomerase) induces cell movement through 12-lipoxygenase-dependent tyrosine phosphorylation and serine dephosphorylation events.
Autocrine motility factor and its receptor expression in musculoskeletal tumors.
Autocrine motility factor and its receptor expressions in human oral squamous cell carcinoma (SCC) cells.
Autocrine motility factor and its receptor: role in cell locomotion and metastasis.
Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization.
Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells.
Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants.
Autocrine motility factor is a growth factor.
Autocrine Motility Factor Modulates EGF-Mediated Invasion Signaling.
Autocrine motility factor promotes epithelial-mesenchymal transition in endometrial cancer via MAPK signaling pathway.
Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Autocrine motility factor receptor expression associates with tumor progression in thymoma.
Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer.
Autocrine motility factor receptor is a marker for a distinct membranous tubular organelle.
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells.
Autocrine Motility Factor Receptor Signaling Pathway Promotes Cell Invasion via Activation of ROCK-2 in Esophageal Squamous Cell Cancer Cells.
Autocrine motility factor secreted by HeLa cells inhibits the growth of many cancer cells by regulating AKT/ERK signaling.
Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells.
Autocrine motility factor signaling enhances pancreatic cancer metastasis.
Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression.
Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion.
Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells.
Autocrine motility factor stimulates the invasiveness of malignant cells as well as up-regulation of matrix metalloproteinase-3 expression via a MAPK pathway.
Autocrine motility factor-receptor gene expression in lung cancer.
Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours.
Autocrine motility factor/phosphoglucose isomerase regulates ER stress and cell death through control of ER calcium release.
Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR).
Biochemical markers in ovarian cancer: possibilities and limitations.
Biochemical mechanisms of tumor invasion and metastases.
Biochemical mechanisms of tumor invasion and metastasis.
Biological characteristics of carcinomatosa pleuritis in orthotopic model systems using immune-deficient rats.
Calibration of the dianionic phosphate group: Validation on the recognition site of the homodimeric enzyme phosphoglucose isomerase.
Carbohydrate-based electrochemical biosensor for detection of a cancer biomarker in human plasma.
Carbon Source Affects Synthesis, Structures, and Activities of Mycelial Polysaccharides from Medicinal Fungus Inonotus obliquus.
Carcinoembryonic antigen and glucose phosphate isomerase in a human colonic cancer model (GW-39).
Carcinoembryonic antigen and phosphohexose isomerase, gammaglutamyl transpeptidase and lactate dehydorgenase levels in patients with and without liver metastases.
Cell motility, a principal requirement for metastasis.
Comparison of phosphohexose isomerase and lactic dehydrogenase activities in plasma, liver, and tumor tissue of tumor-bearing rats.
CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases.
Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration.
Cytoskeletal agents inhibit motility and adherence of human tumor cells.
Design, synthesis, and anticancer activity evaluation of irreversible allosteric inhibitors of the ubiquitin-conjugating enzyme Ube2g2.
Detection of autocrine motility factor in urine as a marker of bladder cancer.
Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation.
Disrupting glucose-6-phosphate isomerase fully suppresses the "Warburg effect" and activates OXPHOS with minimal impact on tumor growth except in hypoxia.
Distribution of tumor-sensitized cells during the induction of permanent tumor regression by chemoimmunotherapy: the use of glucose phosphate isomerase as a marker.
Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence.
Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
Efficacy of Terminalia arjuna (Roxb.) on N-nitrosodiethylamine induced hepatocellular carcinoma in rats.
Emerging views of mitophagy in immunity and autoimmune diseases.
ENZYME STUDIES IN CEREBRAL TUMOURS. LACTATE DEHYDROGENASE, GLUCOSE PHOSPHATE ISOMERASE, ACID AND ALKALINE PHOSPHATASE IN PLASMA, VENTRICULAR CEREBROSPINAL FLUID AND TUMOUR CYST FLUID FROM CASES OF GLIOMA AND CEREBRAL SECONDARY CARCINOMA.
Enzymes of glucose metabolism in carcinoma of the cervix and endometrium of the human uterus.
Evodiamine Induces Apoptosis and Inhibits Migration of HCT-116 Human Colorectal Cancer Cells.
Expression and function of autocrine motility factor receptor in human choriocarcinoma.
Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells.
Expression of Autocrine Motility Factor (AMF) and Its Receptor, AMFR, in Human Breast Cancer.
Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer.
Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma.
Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer.
Expression of autocrine motility factor receptor in cutaneous malignant melanoma.
Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma.
Expression of autocrine motility factor/phosphohexose isomerase in Cos7 cells.
Expression of the AMF/neuroleukin receptor in developing and adult brain cerebellum.
Extragonadal teratocarcinoma derived from embryonal stem cells in chimaeric mice.
Gastric Schwannomas show an obviously increased fluorodeoxyglucose uptake in positron emission tomography: Report of two cases.
Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Glucose-6-phosphate isomerase from Ehrlich ascites tumor cells: purification and some properties.
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
Heregulin regulation of autocrine motility factor expression in human tumor cells.
Higher autocrine motility factor/glucose-6-phosphate isomerase expression is associated with tumorigenesis and poorer prognosis in gastric cancer.
Hyperthermia reduces migration of osteosarcoma by suppression of autocrine motility factor.
Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells.
Immunohistochemical expression of Type IV Collagen and Autocrine Motility Factor Receptor in Odontogenic Tumours.
Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma.
Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3.
Induction via Functional Protein Stabilization of Hepatic Cytochromes P450 upon gp78/Autocrine Motility Factor Receptor (AMFR) Ubiquitin E3-ligase Genetic Ablation in Mice: Therapeutic and Toxicological Relevance.
Inhibition of Non-flux-Controlling Enzymes Deters Cancer Glycolysis by Accumulation of Regulatory Metabolites of Controlling Steps.
Inverse relation of autocrine motility factor receptor and E-cadherin expression following MDCK epithelial cell transformation.
Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
Isozyme pattern in serially xenotransplanted childhood tumors.
Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells.
Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway.
Metabolic Plasiticy in Cancers-Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs.
Molecular association of glucose-6-phosphate isomerase and pyruvate kinase M2 with glyceraldehyde-3-phosphate dehydrogenase in cancer cells.
Monoclonal antibodies against autocrine motility factor suppress gastric cancer.
More on phosphohexose isomerase as a tumor marker.
Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.
Novel N-substituted 5-phosphate-d-arabinonamide derivatives as strong inhibitors of phosphoglucose isomerases: Synthesis, structure-activity relationship and crystallographic studies.
Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta.
Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts.
Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells.
Pectic polysaccharide from corn (Zea mays L.) effectively inhibited multi-step mediated cancer cell growth and metastasis.
Peripherally located occult lung cancer with AMFR expression.
Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer.
Phosphoglucose Isomerase/Autocrine Motility Factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.
Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8.
Phosphohexose isomerase activity as a tumor marker in hepatoma bearing rats (Yoshida A.H. 130).
Phosphohexose isomerase in hypernephroma. Significance as serum tumor marker, comparison to other glycolytic enzymes and isozyme patterns in normal and tumor tissue.
Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein.
Phosphohexose isomerase: a useful parameter in the management of neoplasia.
Potential endocrine function of the glycolytic enzyme glucose-6-phosphate isomerase during implantation.
Preadipocyte stimulating factor in rat serum: evidence for a discrete 63 kDa protein that promotes cell differentiation of rat preadipocytes in primary cultures.
Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression.
Protein factors which regulate cell motility.
Purification and characterization of phosphohexose isomerase from human gastrointestinal carcinoma and its potential relationship to neuroleukin.
Purification of B16-F1 melanoma autocrine motility factor and its receptor.
Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor.
Raft endocytosis of AMF regulates mitochondrial dynamics through Rac1 signaling and the Gp78 ubiquitin ligase.
Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Regulation and biological activities of the autotaxin-LPA axis.
Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis.
Regulation of cell motility via high and low affinity autocrine motility factor (AMF) receptor in human oral squamous carcinoma cells.
Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling.
Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE.
Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14.
Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.
Release of glycolytic enzymes from cultivated tumor cells.
RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer.
Scatter factor and other regulators of cell mobility.
Screening and X-ray Crystal Structure-based Optimization of Autotaxin (ENPP2) Inhibitors, Using a Newly Developed Fluorescence Probe.
Serum phosphohexose isomerase in cancer.
Serum phosphohexose isomerase in cancer. III. As an index of tumor growth in metastatic carcinoma of the prostate.
Serum phosphohexose isomerase in cancer. I. Method of determination and establishment of range of normal values.
Serum phosphohexose isomerase in cancer. II. As an index of tumor growth in metastatic carcinoma of the breast.
Serum phosphohexose isomerase in cancer. IV. Comparison with serum-phosphoglucomutase activity in metastatic cancer.
Serum protein profiles in carcinoma of the kidney.
Serum Th1 and Th17 related cytokines and autoantibodies in patients with Posner-Schlossman syndrome.
Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer.
Silencing of Autocrine Motility Factor Induces Mesenchymal-to-Epithelial Transition and Suppression of Osteosarcoma Pulmonary Metastasis.
Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder.
Studies on glycolytic enzymes in relation to cancer. 3. Clinical significance of serum phosphohexose isomerase and aldolase in cancer of the prostate. A comparative study with serum acid phosphatase and serum alkaline phosphatase.
Studies on glycolytic enzymes in relation to cancer. I. Serum phosphohexose isomerase and aldolase in leukemia.
Studies on glycolytic enzymes in relation to cancer. Part IV: Sera and effusion activities of phosphohexose isomerase, aldolase and lactic dehydrogenase in malignant and benign conditions.
Study of serum phosphohexose isomerase (PHI) levels in the management of head and neck malignancies.
Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
Suppression of melanoma cell motility factor receptor expression by retinoic acid.
Synergistic effects of autocrine motility factor and methyl jasmonate on human breast cancer cells.
Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
The autocrine motility factor (AMF) and AMF-receptor combination needs sugar chain recognition ability and interaction using the C-terminal region of AMF.
The cellular origin of chemically induced tumours.
The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase.
The crystal structure of phosphoglucose isomerase/autocrine motility factor/neuroleukin complexed with its carbohydrate phosphate inhibitors suggests its substrate/receptor recognition.
The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer.
The effect of autocrine motility factor alone and in combination with methyl jasmonate on liver cancer cell growth.
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
The role of autocrine motility factor in tumor and tumor microenvironment.
The role of autotaxin and other motility stimulating factors in the regulation of tumor cell motility.
The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum.
The value of tumour markers in lung cancer.
Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer.
Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis.
Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression.
Tissue glycolytic enzymes in primary breast cancer patients receiving adjuvant chemotherapy.
Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid.
Tumor autocrine motility factor is an angiogenic factor hat stimulates endothelial cell motility.
Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility.
Tumor autocrine motility factor responses are mediated through cell contact and focal adhesion rearrangement in the absence of new tyrosine phosphorylation in metastatic cells.
Tumor autocrine motility factor.
Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide.
Tumor cell autocrine motility factor receptor.
Tumor cell autocrine motility factor.
Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.
Tumor collagenase stimulating factor (TCSF) and tumor autocrine motility factor (TAMF) in bladder cancer.
Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer--an update.
Tumor enzymes and prognosis in transitional cell carcinoma of the bladder: prediction of risk of progression in patients with superficial disease.
Tumor progression- and metastasis-associated proteins identified using a model of locally recurrent rat mammary adenocarcinomas.
Up-regulation of Key Glycolysis Proteins in Cancer Development.
Variants of phosphohexose isomerase in gastrointestinal and mammary carcinoma: isoelectric focusing patterns of normal and tumor tissues derived from surgical specimens of the same patient.
Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (Anticancer effects of 3-bromopyruvate through antagonizing Warburg effect).
Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism.
Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase.
[Behavior of malate dehydrogenase (MDH), FDP-aldolase (ALD) and phosphoglucose isomerase (PGI) in the serum of tumor patients during radiotherapy]
[Behavior of phosphohexose isomerase activity (PHI) in the serum, pleural effusions, and ascitic fluids of subjects with malignant hematologic diseases and tumors]
[Clinical significance of the determination of serum phosphohexose isomerase in malignant neoplasms]
[CLINICAL STUDIES ON SERUM GLYCOLYTIC ENZYMES IN CANCER PATIENTS; ON PHOSPHOHEXOSE ISOMERASE, PHOSPHOGLUCOMUTASE AND LACTIC DEHYDROGENASE ACTIVITIES.]
[Comparative evaluation of lactate dehydrogenase and glucose-6-phosphate isomerase activity in patients with neoplasms]
[Determination of phosphohexose isomerase (PHI) as a diagnostic aid in the prognosis of malignant neoplasms.]
[Enzymatic changes in cancer]
[Possibilities for optimizing radiotherapy of cancers of the ENT area by measuring oncoradiogenic enzyme peaks of glucose-6-phosphate isomerase]
[Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm]
[Principles of tumor invasion and metastasis]
[Progress in research on autocrine motility factor and its receptor in tumor biology].
[Significance of serum autotaxin activity in gastrointestinal disease]
[The activity of isocitra dehydrogenase and of phosphohexose isomerase in the serum of patientwith malignant tumors of the mouth cavity]
[The determination of phosphohexose isomerase in patients with cancer of breast and uterus. A comparison with other tests (author's transl)]
[The role of autocrine motility factor receptor in metastasis]
[The value of urine phosphohexose isomerase activity in comparison with urine cytology. First diagnosis and tumor after-care in patients with cancer of the urinary bladder]
Neoplasms, Squamous Cell
Autocrine Motility Factor Receptor Signaling Pathway Promotes Cell Invasion via Activation of ROCK-2 in Esophageal Squamous Cell Cancer Cells.
Nervous System Diseases
Glucose Phosphate Isomerase Deficiency: High Prevalence of p.Arg347His Mutation in Indian Population Associated with Severe Hereditary Non-Spherocytic Hemolytic Anemia Coupled with Neurological Dysfunction.
Neuroblastoma
Effect of oxygen and glucose availability on the glycolytic rate in neuroblastoma cells under different conditions of culture.
Neurotrophic activity of monomeric glucophosphoisomerase was blocked by human immunodeficiency virus (HIV-1) and peptides from HIV-1 envelope glycoprotein.
Non-alcoholic Fatty Liver Disease
Secreted phosphoglucose isomerase is a novel biomarker of nonalcoholic fatty liver in mice and humans.
Obesity
Pharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in Muscle.
Odontogenic Tumors
Immunohistochemical expression of Type IV Collagen and Autocrine Motility Factor Receptor in Odontogenic Tumours.
Osteoarthritis
Detection of antibodies against glucose 6-phosphate isomerase in synovial fluid of rheumatoid arthritis using surface plasmon resonance (BIAcore).
Osteoarthritis, Knee
Elevated Serum Glucose-6-Phosphate Isomerase Level in Patients with Knee Osteoarthritis.
Osteosarcoma
Effects of protein kinase inhibitors on the cell motility stimulated by autocrine motility factor.
Hyperthermia reduces migration of osteosarcoma by suppression of autocrine motility factor.
Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression.
Silencing of Autocrine Motility Factor Induces Mesenchymal-to-Epithelial Transition and Suppression of Osteosarcoma Pulmonary Metastasis.
Ovarian Neoplasms
Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Microarray analysis of differentially expressed genes associated with human ovarian cancer.
Puncta intended: connecting the dots between autophagy and cell stress networks.
Pancreatic Neoplasms
Autocrine motility factor signaling enhances pancreatic cancer metastasis.
Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells.
Papilloma
Autocrine motility factor-receptor in human bladder-carcinoma - gene-expression, loss of cell-contact regulation and chromosomal mapping.
Paramyxoviridae Infections
Emerging views of mitophagy in immunity and autoimmune diseases.
Parasitic Diseases
Parasites in Bulinus senegalensis (Mollusca: Planorbidae) and their detection.
Parkinsonian Disorders
Emerging views of mitophagy in immunity and autoimmune diseases.
phosphoglucomutase (alpha-d-glucose-1,6-bisphosphate-dependent) deficiency
Acquired erythroenzymopathies in blood disorders: study of 200 cases.
phosphoglycerate kinase deficiency
Enzymatic diagnosis in non-spherocytic hemolytic anemia.
Pleural Effusion
[Behavior of phosphohexose isomerase activity (PHI) in the serum, pleural effusions, and ascitic fluids of subjects with malignant hematologic diseases and tumors]
Pneumonia
[Phosphohexose isomerase and aldolase of the blood serum in pneumonia in children]
Poliomyelitis
Evidence for synteny between a polio receptor gene and glucose phosphate isomerase (GPI) by analysis of human-mouse hybrids.
Priapism
Priapism caused by glucose phosphate isomerase deficiency.
Prostatic Neoplasms
Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells.
Studies on glycolytic enzymes in relation to cancer. 3. Clinical significance of serum phosphohexose isomerase and aldolase in cancer of the prostate. A comparative study with serum acid phosphatase and serum alkaline phosphatase.
Psoriasis
[Phosphohexose isomerase in psoriasis]
[Studies of the activity decrease of phosphoglucose isomerase in erythrocytes of patients with florid psoriasis vulgaris. 3.]
[Studies of the activity of glucose phosphate isomerase in thrombocytes and leukocytes of patients with florid psoriasis vulgaria]
[Studies of the mechanism of the activity diminution of phosphoglucose isomerase in erythrocytes of patients with florid psoriasis vulgaris. I]
[Studies on the inhibiting factor of phosphoglucose isomerase in erythrocytes of patients with florid psoriasis vulgaris]
[Studies on the mechanism of the activity decrease of phosphoglucose isomerase in erythrocytes of patients with florid psoriasis vulgaris. II]
pyruvate kinase deficiency
A combined system for the study of glutathione metabolism in erythrocytes.
Next-Generation Sequencing-Based Diagnosis of Unexplained Inherited Hemolytic Anemias Reveals Wide Genetic and Phenotypic Heterogeneity.
Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach.
Respiratory Insufficiency
Glycolytic enzymes of human fetal and neonatal intraocular fluids.
Retinitis Pigmentosa
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Retinoblastoma
Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling.
Sarcoma
Distribution of tumor-sensitized cells during the induction of permanent tumor regression by chemoimmunotherapy: the use of glucose phosphate isomerase as a marker.
Sheep gene mapping: additional DNA markers included (CASB, CASK, LALBA, IGF-1 and AMH).
Sialadenitis
[Phosphohexose isomerase activity in parotid and submandibular saliva as a parameter in the diagnosis of chronic sialadenitis]
Skin Diseases
[Activity of serum phosphohexose isomerase in some skin diseases]
Spinocerebellar Ataxias
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Squamous Cell Carcinoma of Head and Neck
Autocrine motility factor and its receptor expressions in human oral squamous cell carcinoma (SCC) cells.
Starvation
Down-regulation of Sp1 activity through modulation of O-glycosylation by treatment with a low glucose mimetic, 2-deoxyglucose.
Stillbirth
Glycolytic enzymes of human fetal and neonatal intraocular fluids.
Stomach Neoplasms
Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers.
Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer.
Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer.
Monoclonal antibodies against autocrine motility factor suppress gastric cancer.
Phosphoglucose isomerase gene expression as a prognostic biomarker of gastric cancer.
Subarachnoid Hemorrhage
[The effect of intravenous glucose load on levels of glucose and fructose and activity of glucose-6-phosphate isomerase in serum of patients with subarachnoid hemorrhage]
Thymoma
Autocrine motility factor receptor expression associates with tumor progression in thymoma.
Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma.
Thyroid Neoplasms
Expression of Gp78/Autocrine Motility Factor Receptor and Endocytosis of Autocrine Motility Factor in Human Thyroid Cancer Cells.
Tongue Neoplasms
[Optimizing radiotherapy for carcinomas of the tongue and floor of the mouth. Measurement of oncoradiogenic enzyme peaks of GPI]
Triple Negative Breast Neoplasms
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Puncta intended: connecting the dots between autophagy and cell stress networks.
Tuberculosis
Biochemical characterization of recombinant phosphoglucose isomerase of Mycobacterium tuberculosis.
Crystallization and preliminary X-ray characterization of phosphoglucose isomerase from Mycobacterium tuberculosis H37Rv.
Establishment of an effective TLC bioautographic method for the detection of Mycobacterium tuberculosis H37Ra phosphoglucose isomerase inhibition by phosphoenolpyruvate.
Functional phosphoglucose isomerase from Mycobacterium tuberculosis H37Rv: rapid purification with high yield and purity.
Structural studies of phosphoglucose isomerase from Mycobacterium tuberculosis H37Rv.
Urinary Bladder Neoplasms
Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Detection of autocrine motility factor in urine as a marker of bladder cancer.
Tumor collagenase stimulating factor (TCSF) and tumor autocrine motility factor (TAMF) in bladder cancer.
Urologic Neoplasms
A new method for evaluation of urinary autocrine motility factor and tumor cell collagenase stimulating factor as markers for urinary tract cancers.
Vascular System Injuries
Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells.
Virus Diseases
Friend viral pathogenesis in C57BL/6 reversible DBA/2 allophenic mice.
Whooping Cough
Autocrine motility factor is a growth factor.
Autotaxin is an exoenzyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities.
Identification of B16-F1 melanoma autocrine motility-like factor receptor.
Insulin-like growth factors stimulate chemotaxis in human melanoma cells.
The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells.